Cargando…
Brentuximab Vedotin: A Review in CD30-Positive Hodgkin Lymphoma
Intravenous brentuximab vedotin (ADCETRIS(®)) is a targeted antibody-drug conjugate (ADC) active against CD30-positive cancer cells such as those associated with classical Hodgkin lymphoma (HL). In noncomparative, phase 2 trials and in the real-world setting, salvage therapy with brentuximab vedotin...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7102329/ https://www.ncbi.nlm.nih.gov/pubmed/28190142 http://dx.doi.org/10.1007/s40265-017-0705-5 |